TET2 in Normal and Malignant Hematopoiesis. - Test2 - elhamkhani - TriplyDB

TET2 in Normal and Malignant Hematopoiesis.

TET2 in Normal and Malignant Hematopoiesis.

http://www.wikidata.org/entity/Q39153532

about

Enhancer dysfunction in leukemia.DNA hydroxymethylation levels are altered in blood cells from Down syndrome persons enrolled in the MARK-AGE project.

P2860

Q50028355-1CE82189-87BF-46D0-8165-9F090C39BC3C Q50082527-7E1DDABE-054A-4463-8534-22CEF567D65E

P2860

TET2 in Normal and Malignant Hematopoiesis.

http://www.wikidata.org/entity/Q39153532

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

TET2 in Normal and Malignant Hematopoiesis.

@en

TET2 in Normal and Malignant Hematopoiesis.

@nl

type

label

TET2 in Normal and Malignant Hematopoiesis.

@en

TET2 in Normal and Malignant Hematopoiesis.

@nl

prefLabel

TET2 in Normal and Malignant Hematopoiesis.

@en

TET2 in Normal and Malignant Hematopoiesis.

@nl

P1433

Q39153532-5DCEEB42-F682-4CA6-95BE-6C8F6223D764

P1476

Q39153532-637C8E65-850B-487A-8DAC-C30AEE215EB5

P2093

Q39153532-27D80731-F021-42A0-9170-4435919CF70E

Q39153532-6E708943-CF05-44EF-BC0C-A0584F4D99DD

P2860

Q39153532-05733F9E-0669-47BC-855E-FF6FFE6E5EA0

Q39153532-07A7AF1F-BA92-457E-98B9-04628B6BDF45

Q39153532-0C1785E2-2B11-4AD2-80A6-D65FBA4AA5B8

Q39153532-1505E5FA-D69E-44C7-9A8D-3B4E092682B5

Q39153532-1983C7E0-2AF6-4311-BFA2-C1CED116F6BD

Q39153532-1A7D1EF6-5E0B-4732-BAA3-A930D56E097B

Q39153532-1B73747E-7D78-45F7-A90E-C88A95587ECE

Q39153532-1D6ACFEF-01C0-41F2-8BDD-CAD81A522450

Q39153532-1E5F8083-8D07-471E-A66C-B0720026812C

Q39153532-2449EAF7-68AF-441D-84CB-02936EA763AB

P31

Q39153532-58DD4B87-3C8A-4531-89D1-B68C56ABC37E

P356

Q39153532-EF41091D-8CE9-4993-8866-4FE2BF3CFDBE

P433

Q39153532-09746A89-CD06-4F8A-BE43-D8374461EE38

P478

Q39153532-A86D3F59-EBA6-4EE7-A052-94E1F04998CB

P577

Q39153532-5115D7A2-1369-46CC-A422-6C16AB51AE26

P698

Q39153532-BFE3D1B5-0642-4399-887C-E9B764120E00

P921

Q39153532-029AEECB-7A61-41B5-9591-3A2FBEF08C07

P932

Q39153532-A24CFAC9-99F0-4399-AC96-411CDCA2EBA3

P356

CSHPERSPECT.A026518

P1433

Cold Spring Harbor Perspectives in Medicine

P1476

TET2 in Normal and Malignant Hematopoiesis.

@en

P2093

Robert L Bowman

http://www.w3.org/2001/XMLSchema#string

Ross L Levine

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

DNA demethylation dynamics

P31

scholarly article

P356

10.1101/CSHPERSPECT.A026518

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28242787

http://www.w3.org/2001/XMLSchema#string

P921

P932

5538403

http://www.w3.org/2001/XMLSchema#string